<DOC>
	<DOC>NCT01371435</DOC>
	<brief_summary>This post-marketing surveillance study is designed to detect adverse events (particularly clinically significant adverse drug reactions) occurring in clinical settings and to examine factors likely to affect the safety and efficacy of paroxetine.</brief_summary>
	<brief_title>Drug Use Investigation for PAXIL Tablet</brief_title>
	<detailed_description />
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Patients with depression/depressed state or panic disorder Patients who had been taking PAXIL since before the start of the survey Patients with hypersensitivity to paroxetine Patients taking monoamine oxidase inhibitors (MAOIs) or within 2 weeks of stopping treatment with MAOIs Concomitant use in patients taking pimozide</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>